68 related articles for article (PubMed ID: 9432527)
1. [In vitro diffusion of 5-fluorourcil and tegafur through excized pig cornea].
Grześkowiak E
J Pharm Belg; 1997; 52(5):190-3. PubMed ID: 9432527
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship in Ftorafur (Tegafur) and related 5-FU prodrugs.
Zhuk R
Adv Exp Med Biol; 1998; 431():677-80. PubMed ID: 9598151
[No Abstract] [Full Text] [Related]
3. Species variation in the enantioselective metabolism of tegafur to 5-fluorouracil among rats, dogs and monkeys.
Yamamiya I; Yoshisue K; Ishii Y; Yamada H; Yoshida K
J Pharm Pharmacol; 2014 Dec; 66(12):1686-97. PubMed ID: 25117829
[TBL] [Abstract][Full Text] [Related]
4. Study of carbonyl iron/poly(butylcyanoacrylate) (core/shell) particles as anticancer drug delivery systems Loading and release properties.
Arias JL; Linares-Molinero F; Gallardo V; Delgado AV
Eur J Pharm Sci; 2008 Mar; 33(3):252-61. PubMed ID: 18249100
[TBL] [Abstract][Full Text] [Related]
5. [Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer].
Kojima T; Suzumura K; Kanemitsu T; Miyashita A; Inamura Y; Owa Y; Naruse T
Gan To Kagaku Ryoho; 1998 Mar; 25(4):547-51. PubMed ID: 9530361
[TBL] [Abstract][Full Text] [Related]
6. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Shirasaka T; Taguchi T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
[TBL] [Abstract][Full Text] [Related]
7. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
8. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.
Komatsu T; Yamazaki H; Shimada N; Nagayama S; Kawaguchi Y; Nakajima M; Yokoi T
Clin Cancer Res; 2001 Mar; 7(3):675-81. PubMed ID: 11297264
[TBL] [Abstract][Full Text] [Related]
9. Improved determination of 5-fluorouracil and its prodrug tegafur in pharmaceuticals by large-volume sample stacking in CE.
Yang Y; Liu Q; Tao W; Nie L; Yao S
J Sep Sci; 2007 Dec; 30(18):3296-301. PubMed ID: 18008283
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles of 5-fluorouracil (5-FU) loaded N-succinyl-chitosan (Suc-Chi) for cancer chemotherapy: preparation, characterization--in-vitro drug release and anti-tumour activity.
Yan C; Chen D; Gu J; Qin J
J Pharm Pharmacol; 2006 Sep; 58(9):1177-81. PubMed ID: 16945175
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
12. Estimation of 5-fluorouracil-loaded ethylene-vinyl acetate stent coating based on percolation thresholds.
Guo QH; Guo SR; Wang ZM
Int J Pharm; 2007 Mar; 333(1-2):95-102. PubMed ID: 17110064
[TBL] [Abstract][Full Text] [Related]
13. Effects of the type of release medium on drug release from PLGA-based microparticles: experiment and theory.
Faisant N; Akiki J; Siepmann F; Benoit JP; Siepmann J
Int J Pharm; 2006 May; 314(2):189-97. PubMed ID: 16510257
[TBL] [Abstract][Full Text] [Related]
14. Preliminary evaluation of molecular imprinting of 5-fluorouracil within hydrogels for use as drug delivery systems.
Singh B; Chauhan N
Acta Biomater; 2008 Sep; 4(5):1244-54. PubMed ID: 18448400
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
16. In vitro transcorneal diffusion of the antimicrobial macrolides azithromycin and clarithromycin and the impact on microbial keratitis.
van Eyk AD; Seifart HI; Meyer D; van der Bijl P
Cornea; 2009 May; 28(4):441-6. PubMed ID: 19411964
[TBL] [Abstract][Full Text] [Related]
17. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
Nogué M; Salud A; Batiste-Alentorn E; Saigí E; Losa F; Cirera L; Méndez M; Campos JM; Galan A; Escudero P; Arcusa A; Manzano H; de Mendizábal EV; de Olaguer JP; Boleda M; Guasch I; Vicente P
Eur J Cancer; 2005 Oct; 41(15):2241-9. PubMed ID: 16214045
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
19. Effect of poly(amidoamine) (PAMAM) dendrimer on skin permeation of 5-fluorouracil.
Venuganti VV; Perumal OP
Int J Pharm; 2008 Sep; 361(1-2):230-8. PubMed ID: 18582550
[TBL] [Abstract][Full Text] [Related]
20. Glucose permeability of human, bovine, and porcine corneas in vitro.
Myung D; Derr K; Huie P; Noolandi J; Ta KP; Ta CN
Ophthalmic Res; 2006; 38(3):158-63. PubMed ID: 16401912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
